RT期刊文章SR电子T1女士治疗依从性和复发的风险(P01.193)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP P01.193 O首页P P01.193 VO 80是7补充A1 Bruce Cohen A1托马斯Leist A1 Patricia Coyle A1霍华德Zwibel A1克莱德马科维茨A1马克Tullman年2013 UL //www.ez-admanager.com/content/80/7_Supplement/P01.193.abstract AB目的:调查之间的关系,坚持疾病修饰治疗(DMT)和多发性硬化症(MS)复发的治疗优化女士(MS)研究。背景:药物治疗依从性的程度,患者符合建议治疗剂量和频率。证据表明,对患者治疗依从性是至关重要的减少复发女士缺乏。设计/方法:学者女士在前,一个准,开放研究,被诊断出患有MS和对待glatiramer醋酸或β干扰素由专业药房分发。签署知情同意被返回到药店。研究研究网站登记注销生产指令。在基线反应进入开始,定期。依从性,药物持有率(MPR)来衡量,也来源于药房发货记录。逻辑回归检查医生确诊复发之间的关系和DMT,治疗MPR (< 0.5;> 0.5 < 0.9;> 0.9),治疗女士之前,和以来第一个症状。RESULTS: Across all therapies, the mean MPR for the interim completer cohort of 1,309 was 0.9 (range: 0.1 to 1.0), with 63.8% reaching a two-year MPR >=0.9. Evaluated by categories of MPR, the proportion of participants remaining relapse-free for 24 months increased with increasing MPR, and the proportion with one or more relapses declined with increasing levels of MPR (p < 0.003). Regression analysis revealed the odds of relapse for a patient in the MPR >=0.9 MPR group was 0.5058, 50% of that of a patient in the MPR <=0.5 category (p = 0.02). Being treated with one or more DMT prior to the current one increased the likelihood of relapse 1.7 times (odds ratio = 1.6933) compared to no prior treatments (p < 0.001).CONCLUSIONS: Better DMT adherence is associated with fewer MS relapses. Independent of adherence, one or more DMT changes increase the likelihood of relapses.Supported by: Teva Pharmaceuticals.Disclosure: Dr. Cohen has received personal compensation for activities with Astellis, Biogen Idec, EMD Serono, Genzyme Corporation, Sanofi-Aventis Pharmaceuticals, Inc., and Teva Neurscience. Dr. Cohen has received research support from Teva Neuroscience, the National Institutes of Health, Biogen Idec, EMD Serono, Novartis, and Roche. Dr. Leist has received personal compensation for activities with EMD Serono, Teva Neuroscience, Biogen, Bayer, and Pfizer as a consultant. Dr. Leist has received research support from EMD Serono, Teva Neuroscience, Bayer, ONO, Novartis Daishi, Acorda. Dr. Coyle has received personal compensation for activities with Acorda Therapeutics, Bayer, Biogen Idec, Genentech, Inc., Novartis, Pfizer Inc, Questcor, Roche Diagnostics Corporation, Sanofi-Aventis Pharmaceuticals Corporation, and Teva Neuroscience. Dr. Coyle has received personal compensation in an editorial capacity for NEURA. Dr. Coyle has received research support fromActelion, EMD Serono, and Novartis. Dr. Zwibel has received personal compensation for activities with Acorda Therapeutics, Bayer Pharmaceuticals Corporation, Biogen Idec, Serono, Inc., Genentech, Inc., and Teva Neuroscience as a consultant and/or member of speaker bureau. Dr. Markowitz has received personal compensation for activities with Bayer, Biogen-Idec, Eli Lilly, EMD-Serono, and Teva Neuroscience as a consultant. Dr. Tullman has received personal compensation for activities with Allergan, Inc., Acorda Therapeutics, Biogen Idec, EMD Serono, Novartis, Pfizer Inc, Questcor, Teva Neuroscience, and Sanofi-Aventis Pharmaceuticals, Inc.Monday, March 18 2013, 2:00 pm-6:30 pm